Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Priority
This application, filed 02/05/2025 Claims Priority from Provisional Application 63550933, filed 02/07/2024.
Status of Claims
Claims 1, 18, 29-30, 55-56, 68, 75, 78, 82, 93, 99, 102, 107, 116-117, and 121-124 are currently pending. Claims 2-17, 19-28, 31-54, 57-67, 69-74, 76-77, 79-81, 83-92, 94-98, 100-101, 103-106, 108-115, 118-120, and 125-132 have been canceled.
Claims 1, 18, 29-30, 55-56, 68, 75, 78, 82, 93, 99, 102, 107, 116-117, and 121-124 were examined. Claims 116 and 117 are rejected. Claims 1, 18, 29-30, 55-56, 68, 75, 78, 82, 93, 99, 102, 107, and 121-124 are allowed.
Claim Rejections-35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 116-117 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claims 116 and 117 recite under the groups of R1a “wherein each…. 4- to 10-membered heterocyclyl… of R1a”, however the claims don’t include 4- to 10-membered heterocyclyl as an option of functional groups for R1a. There is insufficient antecedent basis for this limitation in the claims, and the claims are indefinite.
Allowable Subject Matter
The following is a statement of reasons for the indication of allowable subject matter: the compounds of formula (I) of independent claim 1, and the compounds of claim 121 are not taught or suggested by the prior art. Tian et. al., WO 2023072284 A1, publ. 5/4/2023 (English language equivalent US 20250000864 A1) represents the closest prior art. Tian teaches compounds of the structural formula shown below as gonadotropin-releasing hormone antagonists:
PNG
media_image1.png
200
400
media_image1.png
Greyscale
PNG
media_image2.png
200
400
media_image2.png
Greyscale
. While the compounds taught by Tian are structurally similar to the compounds of formula (I), particularly as X1=O, they differ from the instantly claimed compounds by the -CH2-NR1R2 substituent on the ring, which is not included as an option for Rx1 or Rx2.
Information Disclosure Statements
The IDS filed on 5/12/25, 6/17/25, 3/18/26, and 9/11/26 have been considered.
Correspondence
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH PIHONAK whose telephone number is (571)270-7710. The examiner can normally be reached Monday-Friday 9:00-5:30 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached at 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
SARAH . PIHONAK
Primary Examiner
Art Unit 1627
/SARAH PIHONAK/Primary Examiner, Art Unit 1627
Prosecution Insights